Endoprosthesis Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Endoprosthesis Market Trends and Insights

Aging Populations and Rising Osteoarthritis Burden

The endoprosthesis market is supported by an aging population and a growing burden of osteoarthritis. A 2025 study projected continued growth in osteoarthritis prevalence and disability through 2050, with a heavier burden among women and people aged 55 years or older.^{[1]X. Tang et al., “Epidemiological Trends of Osteoarthritis at the Global, Regional, and National Levels From 1990 to 2021 and Projections to 2050,” Arthritis Research & Therapy, link.springer.com} Hip and knee arthroplasty remains underrepresented in health planning despite its effect on mobility and disability. Demand is likely to become more durable in Japan, South Korea, China, and India as larger, older populations gain access to orthopedic services.

Rising Obesity, Sports Injury, and Post-Traumatic Joint Disease Prevalence

Post-traumatic joint disease adds a younger and more physically demanding patient group to the endoprosthesis market. Road traffic injuries caused 1.19 million deaths each year worldwide, and survivors may experience orthopedic trauma that creates later reconstructive needs. This exposure is important in India, Southeast Asia, and Latin America, where injury burdens are high, and trauma care capacity remains uneven. Greater sports participation also increases ligament and cartilage injuries among patients in their 30s and 40s. A 2025 engineering study found that an auxetic femoral stem design reduced stress shielding by 52.3% in a modeled hip replacement setting.^{[2]M. Rahimnejad et al., “Design and Evaluation of Additively Manufactured Personalized 316L Stainless Steel Femoral Stem Incorporating Auxetic Structures to Reduce Stress Shielding Effect,” Engineering Research Express, iopscience.iop.org} These patients can increase demand for cementless fixation, bone-conserving designs, and materials intended for long service life.

Expansion of Robotic-Assisted and Minimally Invasive Arthroplasty

Robotic arthroplasty is becoming a more established capability in high-volume centers in North America and Western Europe. A 2025 study projected that robotic-assisted total knee arthroplasty could approach 70% of U.S. total knee procedures by 2030.^{[3]S. T. Khan et al., “Robotic-Assisted Total Knee Arthroplasty in the USA: Nationwide Adoption Trends Towards 70% by 2030,” Journal of Clinical Orthopaedics and Trauma, doi.org} Smith+Nephew completed its first clinical cases using the CORI XT Handheld Robotics Platform across knee and shoulder arthroplasty in June 2026. A 2026 review found that robotic-assisted total knee arthroplasty adoption rose globally from 2020 to 2025, while capital requirements and surgeon training remained adoption constraints. Platform ownership can strengthen supplier relationships because instruments, planning software, and compatible implants are often selected together.

Growth of Ambulatory Surgical Center and Same-Day Joint Replacement Pathways

Ambulatory surgical centers are changing the care setting for primary joint replacement in the endoprosthesis market. The share of primary total knee surgery completed on an outpatient basis reached 54% in the United States in 2024, compared with less than 5% in 2018. This transition moves greater attention toward predictable operating times, simplified instrument trays, and recovery pathways that do not require a prolonged inpatient stay. A 2025 study assessed 90-day outcomes across ambulatory surgery centers, hospital outpatient departments, and hospitals, reflecting the clinical importance of site-of-care selection. Specialized practices and surgical centers can negotiate directly with manufacturers, which changes purchasing discussions from broad hospital contracts toward cost per case. Implant suppliers need configurations that are suitable for short-stay procedures while maintaining support for complex cases that remain in hospital settings.

High Implant, Operating Room, and Rehabilitation Costs

High costs remain a restraint on the endoprosthesis market, especially where public insurance coverage is limited. Total joint replacement includes the implant, operating room time, anesthesia, imaging, and rehabilitation. The World Health Organization has described arthroplasty as an essential surgery that remains insufficiently included in global health planning despite its role in treating disability. Custom, revision, and tumor reconstruction implants carry greater unit costs and may not be fully covered under diagnosis-related payment systems. Out-of-pocket costs in Sub-Saharan Africa and rural Southeast Asia can prevent clinically appropriate treatment. Manufacturers need lower-cost lines, government partnerships, and payment approaches that expand access without reducing standards of care.

Reimbursement Pressure, Hospital Procurement Consolidation, and Price Compression

Pricing pressure is increasing in several major markets for the endoprosthesis market. In China, centralized procurement reduced the average price of knee prostheses by 82% and increased the importance of lower-cost domestic alternatives. This development can extend access to surgery, but it also reduces margins for suppliers that depend on premium pricing. European group purchasing organizations can create similar pressure through multiyear contracts and larger purchasing pools. Registry evidence becomes more important when hospitals compare products with similar prices and specifications. Smaller manufacturers may face a higher evidence burden if they need to justify a price premium against larger suppliers.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Knee Leads, Hip Gains Ground in Cementless Innovation

Knee endoprostheses held 38.26% of the endoprosthesis market share in 2025. The category includes total, partial, revision, and tumor reconstruction options, which support its broad clinical use. Knee osteoarthritis affected 365 million people globally in 2019 and provides a large procedure base for the category. Demand is tied to a condition that often advances over time and can require replacement when nonoperative care is no longer effective. The category also benefits from extensive surgeon training and well-developed care pathways. Its scale makes it central to purchasing decisions at hospitals, orthopedic clinics, and ambulatory surgical centers.

Hip endoprostheses are forecasted to grow at 12.15% CAGR through 2031. Growth is linked to cementless fixation and bearing surface developments that address compromised bone and longer patient life expectancy. Shoulder replacement is also gaining attention as robotic platforms expand to upper-extremity procedures. Stryker placed Mako Shoulder into full commercial release in March 2026, combining planning software, robotic technology, and compatible reversed shoulder implants. Smaller joints remain lower-volume categories, but their complexity can support higher unit values and more specialized clinical requirements.

By Procedure: Partial Replacement Gains Surgical Momentum

Total replacement procedures accounted for 40.16% of the endoprosthesis market in 2025. They remain the common choice for advanced hip and knee osteoarthritis because clinical practice, surgeon training, and reimbursement are well established. The procedure has a broad implant portfolio and a large installed base of experienced surgeons. Revision procedures account for less volume but require more complex implants and greater operating expertise. These cases are likely to remain concentrated in academic centers and specialized hospitals.

Partial replacement is forecasted to expand at 12.64% CAGR through 2031. Its growth reflects greater confidence in bone-conserving approaches for selected patients who may need future revision options. Such data gives surgeons and procurement teams a clearer basis for comparing revision risk across devices. Resurfacing remains more limited because registry findings have raised concerns about adverse tissue reactions associated with metal-on-metal bearings. Salvage and tumor reconstruction cases are increasingly using custom additive manufacturing when standard implants cannot match the patient’s anatomy.

By Indication: Osteoarthritis Anchors Volume, Trauma Shapes the Next Growth Frontier

Osteoarthritis accounted for 39.16% of the endoprosthesis market share in 2025. It remains the leading reason for elective hip and knee replacement across regions. The World Health Organization states that osteoarthritis affects hundreds of millions of people and can cause pain, disability, and reduced mobility. This pattern provides a stable base for primary procedures, even as health systems alter where those procedures are performed. It also reinforces the value of reliable long-term implant data in populations that live longer after surgery.

Traumatic arthritis and fracture are the fastest-growing indications and are forecasted to expand at 13.47% CAGR through 2031. It is linked to younger, active patients and to regions where road injuries and occupational injuries are significant. Post-traumatic bone loss and congenital deformity represent smaller volumes, but they often require modular or patient-specific implants. Rheumatoid and inflammatory arthritis can require specialized designs because bone damage may be more severe, and patients may be younger.

By End-User: Hospitals Lead, Orthopedic Clinics Accelerate

Hospitals and surgical centers held 42.23% of the endoprosthesis market in 2025. They remain essential for complex primary procedures, revisions, tumor reconstruction, and patients who need extensive post-operative support. Hospital procurement also remains important in markets where centralized purchasing determines product access. Larger institutions can use registry evidence and volume data to standardize implant choices. 

Orthopedic clinics are forecasted to grow at an 11.73% CAGR through 2031. Specialization allows musculoskeletal practices to establish dedicated operating rooms and affiliations with ambulatory surgical centers. Outpatient recovery protocols also move more follow-up and rehabilitation coordination outside the hospital. The endoprosthetics industry is consequently serving a broader set of purchasers and care settings than it did when hospital inpatient care dominated joint replacement.

Geography Analysis

North America held 47.34% of the endoprosthesis market share in 2025. The region is supported by high procedure volumes, broad premium implant adoption, and early use of robotic systems. Outpatient primary total knee procedures reached 54% of U.S. procedures in 2024, which shows how strongly site-of-care choices are changing purchasing requirements. The United States remains the largest source of regional volume, while Canada provides predictable demand through provincial systems with stricter price conditions. Mexico is expanding orthopedic capacity through private hospital networks in large cities. These differences require manufacturers to balance premium technology offerings with pricing and reimbursement realities across the region.

Europe is a major endoprosthesis market because Germany, the United Kingdom, France, Italy, and Spain have mature orthopedic systems. National joint registries have a strong influence on purchasing by linking implant selection to survivorship evidence. European Medical Device Regulation requirements increase the importance of post-market clinical follow-up for Class III orthopedic implants. The United Kingdom also has separate post-Brexit requirements, which add regulatory work for suppliers. These systems reward manufacturers that can provide consistent evidence across long follow-up periods.

Asia-Pacific is projected to grow at a 14.21% CAGR through 2031, the fastest rate among geographic segments. China, Japan, India, South Korea, and Australia each contribute different demand conditions, from public procurement to premium registry-led selection. China’s centralized procurement policy reduced average knee prosthesis prices by 82% and strengthened domestic joint suppliers by volume. Japan, South Korea, and Australia offer a different opportunity because older populations and established clinical standards support advanced implant adoption. The Middle East, Africa, and South America remain smaller segments, but private hospital expansion, government health investment, road injury exposure, and lower competitive saturation create room for carefully priced offerings.